1. Winters JL, Pineda AA: New directions in plasma exchange. Curr Opin Hematol2003, 10:424-428
2. Grima KM: Therapeutic apheresis in hematological and oncological diseases. JClin Apheresis 2000, 15:28-52
3. Winters JL, et al.: Therapeutic aphereis in renal and metabolic diseases. J clinApheresis 2000, 15:53-73
4, Coppo P et al.: High-dose plasma infusion versus plasma exchange as earlytreatment of thrombotic thrombocytopenic purpura.hemolytic-uremic syndrome.Medicine(Baltimore) 2003, 82:27-38
5. Haas M et al.: The LDH ratio as a marker for response to plasma exchange n HUS/TTP of the **. Clin Nephrol 2002, 57:414-420
6. oriYetal.: Predicting response to plasma exchange inpatients with thromboticthrombocytopenic purpura with measurement of vWF-cleaving protease activity.Transfusion 2002, 42:572-580
7. Winstein R: Therapeutic apheresis in neurological disorders. J Clin Apheresis200, 15:74-128
8. Raphael JC et al.: Plasma exchange for Guillain-Barre syndrome. CochraneDatabase Syst Rev 2002,2: CD001798
9. Lyu RK et al.: Plasma exchange versus double filtration plasmapheresis in thetreatment of Guillain-Barre syndrome. Ther Apher 2002, 6:163-166
10. Mori M et al.: Plasmapheresis and Miller Fisher syndrome: ananlysis of 50consecutive cases. J Neurol Neurosurg Psych 2002, 72:680
11. Kambara C et al.: Miller Fisher syndrome and plasmapheresis. Ther Apher 2002,6:450-453
12. Gajdos P et al.: Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002, 4: CD002750
13.AtamanKetal.: Short-term cardiovascular effects of plasmapheresis innorepinephrine-refractory septic shock. Intensive Care Med 2002, 28:1164-1167
14. Busund R et al.: Plasmapheresis in severe sepsis and septic shock:aprospective, randomised, controlled trial. Intensive Care Med 2002,28:1434-1439
15. Aasarod K et al.: Clinical outcome of petients with Wegener's granulomatosistreated with plasma exchange. BloodPurif 2002, 20:167-173